JP2018523689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523689A5 JP2018523689A5 JP2018508757A JP2018508757A JP2018523689A5 JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5 JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- kit
- composition according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514760.6 | 2015-08-19 | ||
| GBGB1514760.6A GB201514760D0 (en) | 2015-08-19 | 2015-08-19 | Compounds and method of use |
| PCT/GB2016/052575 WO2017029517A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523689A JP2018523689A (ja) | 2018-08-23 |
| JP2018523689A5 true JP2018523689A5 (enExample) | 2019-07-25 |
Family
ID=54258859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508757A Withdrawn JP2018523689A (ja) | 2015-08-19 | 2016-08-19 | ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10668077B2 (enExample) |
| EP (1) | EP3337477B1 (enExample) |
| JP (1) | JP2018523689A (enExample) |
| KR (1) | KR20180064387A (enExample) |
| CN (2) | CN113786409B (enExample) |
| AU (1) | AU2016307885B2 (enExample) |
| CA (1) | CA2995898A1 (enExample) |
| DK (1) | DK3337477T3 (enExample) |
| ES (1) | ES2939815T3 (enExample) |
| FI (1) | FI3337477T3 (enExample) |
| GB (1) | GB201514760D0 (enExample) |
| HR (1) | HRP20230376T1 (enExample) |
| HU (1) | HUE061615T2 (enExample) |
| IL (1) | IL257499A (enExample) |
| LT (1) | LT3337477T (enExample) |
| MX (1) | MX2018001926A (enExample) |
| PL (1) | PL3337477T3 (enExample) |
| PT (1) | PT3337477T (enExample) |
| RS (1) | RS64095B1 (enExample) |
| SI (1) | SI3337477T1 (enExample) |
| SM (1) | SMT202300063T1 (enExample) |
| WO (1) | WO2017029517A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200007B2 (en) | 2009-08-20 | 2015-12-01 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| WO2020055840A1 (en) * | 2018-09-11 | 2020-03-19 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| EP3854397A4 (en) * | 2018-09-18 | 2022-07-13 | Kabushiki Kaisha Yakult Honsha | COMBINATION OF CANCER THERAPY USING QUINOLINECARBOXAMIDE DERIVATIVE |
| WO2020174420A1 (en) * | 2019-02-27 | 2020-09-03 | Astrazeneca Ab | Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor |
| CN111904958B (zh) * | 2019-05-09 | 2022-09-13 | 浙江大学 | Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用 |
| GB201909468D0 (en) * | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| BE786081A (fr) * | 1971-07-13 | 1973-01-10 | Uniroyal Sa | Appareil et procede pour maintenir les tringles des bourrelets de pneu |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CN1250294A (zh) * | 1999-07-27 | 2000-04-12 | 邮电部武汉邮电科学研究院 | 以太网与同步数字体系或同步光网络融合的适配方法 |
| ES2310166T3 (es) | 1999-08-03 | 2009-01-01 | Lilly Icos Llc | Composicion farmaceutica que contiene tadalafil. |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| ATE503743T1 (de) | 2000-04-27 | 2011-04-15 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
| US6635640B2 (en) | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1724267B1 (en) | 2004-02-26 | 2013-11-06 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| CA2567883A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| EP2354139A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| JP2009523812A (ja) | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
| KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제제로서의 피리미딘 유도체 |
| EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| ATE510840T1 (de) | 2006-06-26 | 2011-06-15 | Ucb Pharma Sa | Kondensierte thiazol-derivate als kinasehemmer |
| CN101501035B (zh) * | 2006-08-08 | 2013-01-23 | 中外制药株式会社 | 作为pi3k抑制剂的嘧啶衍生物及其用途 |
| CA2669399A1 (en) | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| US20080312199A1 (en) | 2006-12-15 | 2008-12-18 | Glinsky Gennadi V | Treatments of therapy resistant diseases and drug combinations for treating the same |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| EP2139332A4 (en) | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| EP2205242B1 (en) * | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US20110201608A1 (en) | 2008-08-05 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and use thereof as medicines |
| US20110257170A1 (en) | 2008-10-03 | 2011-10-20 | Merck Serono Sa | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| US9200007B2 (en) * | 2009-08-20 | 2015-12-01 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN101849934B (zh) * | 2010-05-25 | 2011-11-09 | 苏州大学 | 一种磷脂酰肌醇-3-激酶抑制剂及其应用 |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP2922851B8 (en) | 2012-11-20 | 2017-09-27 | F. Hoffmann-La Roche AG | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| ES2688815T3 (es) | 2013-05-10 | 2018-11-07 | Karus Therapeutics Limited | Inhibidores de histona desacetilasa novedosos |
| SG10201709926VA (en) * | 2013-05-30 | 2017-12-28 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2015
- 2015-08-19 GB GBGB1514760.6A patent/GB201514760D0/en not_active Ceased
-
2016
- 2016-08-19 EP EP16756763.5A patent/EP3337477B1/en active Active
- 2016-08-19 CN CN202111104917.2A patent/CN113786409B/zh active Active
- 2016-08-19 HU HUE16756763A patent/HUE061615T2/hu unknown
- 2016-08-19 MX MX2018001926A patent/MX2018001926A/es unknown
- 2016-08-19 KR KR1020187007564A patent/KR20180064387A/ko not_active Withdrawn
- 2016-08-19 LT LTEPPCT/GB2016/052575T patent/LT3337477T/lt unknown
- 2016-08-19 CA CA2995898A patent/CA2995898A1/en not_active Abandoned
- 2016-08-19 ES ES16756763T patent/ES2939815T3/es active Active
- 2016-08-19 PL PL16756763.5T patent/PL3337477T3/pl unknown
- 2016-08-19 SI SI201631666T patent/SI3337477T1/sl unknown
- 2016-08-19 US US15/753,353 patent/US10668077B2/en active Active
- 2016-08-19 JP JP2018508757A patent/JP2018523689A/ja not_active Withdrawn
- 2016-08-19 RS RS20230255A patent/RS64095B1/sr unknown
- 2016-08-19 PT PT167567635T patent/PT3337477T/pt unknown
- 2016-08-19 DK DK16756763.5T patent/DK3337477T3/da active
- 2016-08-19 AU AU2016307885A patent/AU2016307885B2/en not_active Ceased
- 2016-08-19 FI FIEP16756763.5T patent/FI3337477T3/fi active
- 2016-08-19 CN CN201680057437.6A patent/CN108348505B/zh active Active
- 2016-08-19 HR HRP20230376TT patent/HRP20230376T1/hr unknown
- 2016-08-19 WO PCT/GB2016/052575 patent/WO2017029517A1/en not_active Ceased
- 2016-08-19 SM SM20230063T patent/SMT202300063T1/it unknown
-
2018
- 2018-02-13 IL IL257499A patent/IL257499A/en unknown
-
2020
- 2020-04-22 US US16/855,758 patent/US11291669B2/en active Active
-
2022
- 2022-03-01 US US17/684,020 patent/US12257254B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523689A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| CN111886006B (zh) | 治疗肥大细胞增多症的组合疗法 | |
| US9937174B2 (en) | Combinations of histone deacetylase inhibitors and bendamustine | |
| WO2021262484A1 (en) | Combination therapy for treatment of cancer | |
| US20160287605A1 (en) | Combination therapy | |
| JP2013528600A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| CN101808636B (zh) | 黑色素瘤的治疗 | |
| JPWO2022250170A5 (enExample) | ||
| JP2015522592A5 (enExample) | ||
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| EP2538935B1 (en) | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine | |
| JP2016538295A5 (enExample) | ||
| Kawahara et al. | Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas | |
| US20230060792A1 (en) | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy | |
| CN101605541A (zh) | 有效治疗化疗药物引起的周围神经毒性的吡咯并[1,2-a]咪唑二酮 | |
| RU2341260C2 (ru) | Комбинации, включающие производные эпотилона и алкилирующие агенты | |
| US9907797B2 (en) | Combination therapies for overcoming resistance to mitotic agents during chemotherapy | |
| CN110891574A (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| WO2025202854A1 (en) | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer | |
| WO2020106454A3 (en) | Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction |